Dengning Xia | Pharmacology | Best Researcher Award

Published on by Research Awards

Prof. Dengning Xia | Pharmacology | Best Researcher Award 

Prof. Dengning Xia, Sun Yat-sen University, China

Dr. Dengning Xia is an Associate Professor and Principal Investigator at the School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, China. With a Ph.D. in Pharmaceutics and international training experience in Denmark and the U.S., his research focuses on industrial pharmaceutics, biopharmaceutics, and biomedical engineering for drug and vaccine delivery. His work explores microneedle systems, nucleic acid and oral delivery, and translational drug formulation. He has received numerous talent awards, serves on editorial boards of leading journals, and has published over 40 peer-reviewed papers in top-tier pharmaceutical and biomedical journals.

Author Profile

Google  Scholar

🎓 Early Academic Pursuits

Dr. Dengning Xia’s academic journey reflects a strong and consistent commitment to the pharmaceutical sciences. He began his higher education with a Bachelor’s degree in Pharmacy from the School of Pharmacy, Hunan University of Chinese Medicine in 2005. Demonstrating early promise and dedication, he continued his studies with a Master’s degree in Pharmaceutics from West China School of Pharmacy, Sichuan University (2005–2008), a program known for its rigorous training and focus on drug delivery systems. Pushing the boundaries of academic excellence, Dr. Xia earned his Ph.D. in Pharmaceutics from Shenyang Pharmaceutical University (2008–2011). As part of his doctoral training, he participated in a joint research program at the University of Copenhagen in Denmark (2011), gaining valuable international research exposure and advancing his expertise in advanced drug delivery systems. His early academic experiences laid the foundation for a research career focused on innovation in pharmaceutical technologies.

🧪 Professional Endeavors

Dr. Xia’s professional journey spans globally recognized institutions and industry positions, reflecting his deep-rooted experience across both academic and applied pharmaceutical sciences. Following a brief stint as Formulation Project Leader at Shanghai Haini Pharmaceutical Co., Ltd. (2011–2012), he moved into academia and research as a Postdoctoral Fellow and later Associate Researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (2012–2017). His passion for translational research took him to the United States, where he worked at the University of Connecticut and later as a Postdoctoral Fellow and Research Scientist at the School of Chemical and Biomolecular Engineering, Georgia Institute of Technology (2017–2020). Since 2020, Dr. Xia has been serving as an Associate Professor (PI) at the School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, a role he assumed under the prestigious “Hundred Talents Program.”

🔬 Contributions and Research Focus

Dr. Xia’s research spans industrial pharmaceutics, biopharmaceutics, and biomedical engineering, with a consistent focus on overcoming biological barriers in drug and vaccine delivery. His multidisciplinary work has led to impactful contributions in the following areas:

  1. 🧬 Overcoming Biological Barriers in Drug Delivery: He has developed innovative microneedle technologies, gastrointestinal and ocular drug delivery systems, and long-acting formulations that enhance therapeutic efficacy while minimizing toxicity.

  2. 💉 Vaccine and Nucleic Acid Delivery Systems: Leveraging cutting-edge piezoelectric systems and novel carriers, Dr. Xia is pioneering advancements in gene and vaccine delivery platforms, including low-cost electroporators and skin-based delivery.

  3. 🏥 Clinical Translation: His translational research bridges laboratory discoveries with clinical applications, facilitating the development of scalable pharmaceutical formulations and devices.

With over 40 high-impact publications, including in PNAS, Advanced Functional Materials, Journal of Controlled Release, and Science Robotics, Dr. Xia’s work is globally cited and well-respected.

🏆 Accolades and Recognition

Dr. Xia’s innovative work has earned him numerous awards and prestigious appointments:

  • “Pearl River Talents Program” Young Top-notch Talent – Guangdong Province

  • Pengcheng Peacock Plan – High-level Talent, Shenzhen

  • Outstanding Young Talent – Sanofi-CAS Shanghai Institute of Biological Sciences

  • Youth Innovation Promotion Association Member – Chinese Academy of Sciences

He serves on editorial boards for top journals such as the European Journal of Pharmaceutics and Biopharmaceutics and Asian Journal of Pharmaceutical Sciences, and is a trusted peer reviewer for over 10 major journals and national grant programs.

🌍 Impact and Influence

Dr. Xia’s work has significantly advanced the field of drug delivery science, particularly through his innovations in microneedle patches, oral and ocular formulations, and nucleic acid therapeutics. His research not only addresses practical clinical challenges but also offers low-cost, accessible solutions for global healthcare, such as vaccine patches for diseases like SARS-CoV-2 and Ebola. His collaborative projects with international scientists from the U.S., China, and Europe have amplified his impact, making him a key influencer in pharmaceutical formulation research and a valuable mentor to the next generation of scientists.

🧭 Legacy and Future Contributions

Looking ahead, Dr. Xia’s legacy will likely be defined by his ability to combine academic rigor with real-world solutions. His contributions to microneedle-based technologies and oral delivery systems are poised to transform how vaccines and drugs are administered, especially in low-resource settings. As a principal investigator and educator at Sun Yat-sen University, he continues to mentor emerging scientists, foster international collaborations, and push the boundaries of what’s possible in drug delivery science. With his track record, Dr. Xia is set to play a leading role in the next generation of pharmaceutical innovation, particularly in the realms of biodegradable drug carriers, smart delivery systems, and personalized medicine.

✍️Publication Top Notes

📘Preparation of stable nitrendipine nanosuspensions using the precipitation–ultrasonication method for enhancement of dissolution and oral bioavailability

Author: D Xia, P Quan, H Piao, H Piao, S Sun, Y Yin, F Cui

Journal: European journal of pharmaceutical sciences 

Year: 2010

📘Devices, Systems, and Methods for Facilitating Tissue Delivery of Drug

Author: MS Bhamla, G Byagathvalli, D Xia, MR Prausnitz

Journal: US Patent App

Year: 2023

📘Inflammation-retentive hyaluronic acid-mesalamine conjugate for enhanced oral therapy in ulcerative colitis

Author: Y Hou, J Yao, J Hu, D Xia

Journal: International Journal of Biological Macromolecules

Year: 2025

Pratiksha Kshirsagar | Pre-clinical pharmacology | Best Researcher Award | 13450

Published on by Research Awards

Ms. Pratiksha Kshirsagar | Pre-clinical pharmacology | Best Researcher Award

Ms. Pratiksha Kshirsagar, University of Nebraska Medical Center, United States

Ms. Pratiksha Kshirsagar is a dedicated pharmaceutical scientist currently pursuing her Ph.D. in Pharmaceutical Sciences at the University of Nebraska Medical Center (UNMC), USA. With strong academic credentials and hands-on research experience in both India and the U.S., she specializes in bioanalytical method development, preclinical pharmacokinetics, and drug delivery systems. Her work includes the development and validation of LC-MS/MS methods and conducting in vitro and in vivo DMPK studies for novel therapeutics targeting medulloblastoma. She has co-authored several peer-reviewed publications and presented her findings at national and international conferences. Ms. Kshirsagar is also a recipient of the UNMC Dean of Graduate Studies Conference Attendance Award and remains committed to advancing pharmaceutical research and translational drug development.

Profile

ORCID

🎓 Early Academic Pursuits

Pratiksha Kshirsagar’s academic journey is marked by consistent dedication and a keen interest in pharmaceutical sciences. Her educational foundation was laid at Savitribai Phule Pune University, where she earned both her Bachelor of Pharmacy (2016–2020) with an SGPA of 7.7/10 and a Master of Pharmacy in Pharmaceutics (2020–2022), graduating with distinction (SGPA: 8.96/10). These formative years laid the groundwork for her strong research acumen and laboratory skills. Keen to explore further, she transitioned to the University of Nebraska Medical Center (UNMC), USA, where she pursued a Master of Pharmaceutical Sciences (2022–2024). Her academic growth culminated in her enrollment in the Ph.D. program in Pharmaceutical Sciences (2024–2029). With a GPA of 3.6/4.0, her progress has been both steady and impressive. Simultaneously, she earned a Certificate in Applied Biostatistics with a perfect GPA of 4.0/4.0, showcasing her commitment to interdisciplinary learning and data-driven research.

🧪 Professional Endeavors

Pratiksha’s professional experience is deeply intertwined with her academic path, reflecting a rare blend of scholarly rigor and hands-on application. At UNMC, under the mentorship of Dr. Daryl J. Murry, she has worked extensively as a graduate research assistant and student researcher, contributing to the development and validation of LC-MS/MS bioanalytical methods for novel small molecules and RIPTACs. Her earlier professional journey in India involved impactful research under Dr. Smita S. Pimple, where she explored micro-emulsions using essential oils and carrier oils for skincare applications. This early exposure to formulation science, coupled with analytical chemistry, gave her a solid foundation in pharmaceutics and laboratory research.

🔬 Contributions and Research Focus

Pratiksha’s primary research focus lies in drug metabolism and pharmacokinetics (DMPK), with an emphasis on preclinical evaluation of novel therapeutic agents. Her notable contributions include the in-depth pharmacokinetic analysis of EPZ015666 and JNJ-64619178 for medulloblastoma treatment, reflecting her role in advancing pediatric cancer therapy.

Her technical expertise spans several key areas:

  • LC-MS/MS bioanalytical method development

  • In-vitro studies like metabolic stability, protein binding, and drug transporter assays

  • In-vivo animal studies, including oral/IV dosing and tissue distribution

  • Use of Phoenix WinNonlin, GraphPad Prism, and other analytical tools for pharmacokinetic modeling

Moreover, she contributed to the design, characterization, and stability testing of advanced nano drug delivery systems such as S-SNEDDS (Solid Self-Nanoemulsifying Drug Delivery System), which demonstrates her interdisciplinary knowledge.

🏅 Accolades and Recognition

Pratiksha’s dedication has earned her notable recognition throughout her academic and research journey. She was awarded the UNMC Dean of Graduate Studies Conference Attendance Award in 2023, underscoring her academic excellence and potential for contribution at scientific forums.

She actively participated in esteemed conferences such as:

  • American Association of Pharmaceutical Scientists (AAPS), Oct 2023

  • UNMC College of Pharmacy Research Day, May 2023

  • CHRI Pediatric Research Forum, May 2023

In earlier academic years, she was involved in state and national level conferences and poster competitions, including the Medical Coding & E-Poster Competition (2020) and a State Level Seminar on Natural Products Research (2018).

🌍 Impact and Influence

Pratiksha’s research holds real-world significance. Her work on small molecule therapeutics for medulloblastoma contributes to the body of knowledge addressing rare pediatric brain cancers, potentially guiding future clinical interventions. Her cross-functional approach—merging analytical chemistry, pharmacology, and pharmaceutical formulation—makes her an invaluable contributor to translational medicine. She has also co-authored several scholarly publications and book chapters on nanotechnology, drug delivery, and antiviral drug challenges, reinforcing her growing influence in the academic community. These contributions are cited in peer-reviewed journals and academic textbooks, evidencing her thought leadership.

🔮 Legacy and Future Contributions

As Pratiksha continues her Ph.D. journey, her trajectory suggests a future as a leading scientist in pharmaceutical research and drug development. Her interests align with solving complex challenges in drug delivery, pharmacokinetics, and personalized medicine. Looking ahead, she aims to bridge the gap between bench-side research and bedside applications, translating scientific breakthroughs into therapeutic realities. Whether in academia, industry, or clinical collaborations, her vision is clear: to contribute meaningfully to global health innovation.

📄 Publication Top Notes

Crossing the Blood–Brain Barrier: Innovations in Receptor- and Transporter-Mediated Transcytosis Strategies

Contributors: Ling Ding; Pratiksha Kshirsagar; Prachi Agrawal; Daryl J. Murry

Journal: Pharmaceutics

Year: 2025

Preparation and Characterization of Advanced Nano medicine For Malaria: Box Behnken Design Approach

Contributors: Anuradha G. More; Parag R. Potbhare; Padmaja S. Kore; Praveen D. Chaudhari; Pratiksha U. Kshirsagar; Radhika R. Baheti; Surbhi C. Gupta

Journal: International Journal of Life Science and Pharma Research

Year: 2022

Zu-Chian Chiang | Biochemistry | Best Researcher Award | 13347

Published on by Research Awards

Dr. Zu-Chian Chiang | Biochemistry | Best Researcher Award 

Dr. Zu-Chian Chiang, Fujian Normal University, China

Dr. Zu-Chian Chiang is a postdoctoral fellow at the Biomedical Research Center of Southern China, Fujian Normal University, China, with a rich background in materials and chemical engineering. His research contributions span antibody-drug conjugates (ADCs), functional peptide synthesis, biomaterials for regenerative medicine, and aptamer-based cancer therapy. His work has geographic impact across Taiwan and Mainland China, contributing to translational medicine and oncology through collaborative efforts with prestigious institutions like Academia Sinica and National Taiwan University. His applied research in ADCs and biomaterial scaffolds directly supports cancer treatment innovations. Notable projects include the development of CD47-targeting ADCs for non-small cell lung cancer, and thalidomide-PD1 combinations for enhanced immunotherapy. His publications in Frontiers in Oncology, PLOS ONE, and Current Pharmaceutical Biotechnology highlight his influence in drug delivery and cancer therapeutics. In the vector control domain, his scaffold research contributes to potential localized drug delivery systems. Dr. Chiang has received awards such as the Science and Technology Commissioner honor from Quanzhou and the Biotech Elite Training Award. His achievements exemplify impactful biomedical research with real-world therapeutic implications.

Profile

Scopus

🌱 Early Academic Pursuits

Dr. Zu-Chian Chiang embarked on his scientific journey with a passion for chemistry and materials science. He earned his Master’s Degree in Chemistry from Tunghai University, Taiwan (2005–2007), under the guidance of Prof. Feng-Di Lung. Building on this solid foundation, he pursued his Ph.D. in Materials and Chemical Engineering at National United University, Taiwan (2008–2014). During his doctoral studies, he was mentored by Prof. An-Chong Chao and co-advised by Dr. Guo-Chung Dong, focusing on biomaterials and nanomedicine.

Even as a student, Dr. Chiang demonstrated exceptional academic capabilities, earning scholarships and recognition for his innovative research. His academic training laid the groundwork for his future contributions in biomedical engineering and cancer therapeutics.

🧪 Professional Endeavors

Dr. Chiang has held several prestigious postdoctoral positions. His professional journey reflects a commitment to interdisciplinary collaboration and translational research:

  • Postdoctoral Fellow at the Biomedical Research Center of Southern China, Fujian Normal University (2019–Present), working under Prof. Qi Chen.

  • Postdoctoral Fellow at the Institute of Biological Chemistry, Academia Sinica, Taiwan (2016–2019), contributing to the Taiwan Protein Project (TPP) and the Technical Support Platform Spindle Project (TSPA).

  • Postdoctoral Fellow at the Clinical Trial Center, National Taiwan University Hospital (2015–2016), supported by Taiwan’s prestigious Biotech Elite Training Program.

Throughout these roles, Dr. Chiang has engaged in cutting-edge biomedical research with direct implications for drug development and clinical applications.

🔬 Contributions and Research Focus

Dr. Chiang’s research centers on innovative therapeutic materials and drug delivery systems, particularly in cancer therapy. His core interests include:

  • Antibody-Drug Conjugates (ADCs): Targeted cancer therapies such as HER2-positive and CD47-specific ADCs.

  • Functional Peptide Synthesis for bone tissue engineering and cancer inhibition.

  • Bio-Micro-Macro Molecular Materials for regenerative medicine.

  • Aptamer Development as modulators in therapeutic settings.

Notable publications include research on CD47-targeting ADCs (Frontiers in Oncology, 2022) and HER2-positive ADCs (PLOS ONE, 2020). His work on dexamethasone-immobilized chitosan scaffolds and chitosan-caffeic acid hybrids also provides valuable insights into localized drug delivery and tissue engineering.

🏆 Accolades and Recognition

Dr. Chiang’s dedication has been acknowledged through numerous awards:

  • 🥇 Science and Technology Commissioner, Quanzhou, Fujian Province (2020)

  • 🥇 Biotech Elite Training Award, National Taiwan University & Ministry of Science and Technology (2016)

  • 🥇 Chung Hwa Rotary Doctoral Program Award, Taiwan (2012)

  • 🥇 Outstanding Doctoral Scholarship, National United University (2010)

  • 🥇 Master’s Program Scholarship, Hunan Fellow Association of Taiwan (2007)

  • 🥇 Rotary Leadership Award, Miaoli Southeastern Xindong Satellite Rotary Club (2017)

These accolades affirm his position as a respected figure in the fields of biomedical chemistry and translational medicine.

🌍 Impact and Influence

Dr. Chiang’s work has made a geographic impact spanning Taiwan and Mainland China. His collaborative research in academia and clinical centers bridges the gap between laboratory research and therapeutic application. He actively contributes as a peer reviewer for the International Journal of Biological Macromolecules, influencing scientific standards and publication quality globally.

He is also engaged in community service through leadership in Rotary International, fostering science-driven community development and education.

🌟 Legacy and Future Contributions

Dr. Chiang’s legacy is being built on the foundation of scientific excellence, mentorship, and translational impact. His research not only pushes the boundaries of biomedical engineering but also aims to enhance the effectiveness of cancer treatments in clinical practice. With a commitment to developing next-generation targeted therapies and biomaterial scaffolds, Dr. Chiang is poised to shape the future of personalized medicine and regenerative technologies.

Looking ahead, he aims to establish interdisciplinary collaborations and contribute to global health initiatives, making life-saving therapies more effective and accessible.

Publication Top Notes

Development of Novel CD47-Specifific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo. 

Author: Z.C., Chiang, Zu Chian, S., Fang, Shubin, Y., Shen, Yangkun, … J., Lin, Jizhen, Q., Chen, Qi

Journal: Frontiers in Oncology,

Year: 2022

Preparation and characterization of dexamethasone-immobilized chitosan scaffold

Author: Z.C., Chiang, Zu Chian, S., Yu, Shuhuei, A., Chao, Anchong, G.C., Dong, Guo Chung

Journal: Journal of Bioscience and Bioengineering, 

Year: 2012

 

Ferdinando D’Amico | Medicine and Health Sciences | Best Researcher Award

Published on by Research Awards

Ferdinando D’Amico | Medicine and Health Sciences | Best Researcher Award

Dr Ferdinando D’Amico, IRCCS San Raffaele Hospital, Italy

Dr. Ferdinando D’Amico is a distinguished gastroenterologist at IRCCS San Raffaele Hospital in Milan, Italy, with expertise in gastroenterology and endoscopy. 🎓 He completed his residency in Gastroenterology/Digestive Diseases and earned his PhD at Hunimed University, focusing on histology in inflammatory bowel diseases. His academic journey includes a degree in Medicine and Surgery from “Cattolica del Sacro Cuore” University, where he researched intestinal permeability and atherosclerosis. 🏥 His training included internships in gastroenterology and cardiology at “Agostino Gemelli” Hospital in Rome. Dr. D’Amico is proficient in English and French, and skilled in digital communication. 🌍🔬

Publication profile

Scopus

Education 

🎓 From 2003 to 2008, attended Classical High School, graduating with highest honours. From 2009 to 2015, pursued a Degree in Medicine and Surgery at “Cattolica del Sacro Cuore” University, Rome, also graduating with highest honours. 🏆 The dissertation, titled “Alterations in Intestinal Permeability and Inflammation: A Novel Potential Mechanism of Atherosclerosis,” was supervised by Professor Filippo Crea. 📜 Currently registered with the Ordine Provinciale dei Medici Chirurghi e degli Odontoiatri di Caserta, registration number 7593. 🩺

Experience

From November 1, 2016, to November 2, 2020, [Name] completed their residency in Gastroenterology/Digestive System Diseases at Hunimed University in Pieve Emanuele, Italy, graduating with highest honors. They then pursued a Ph.D. at the same institution, focusing on “The Role of Histology in Inflammatory Bowel Diseases,” under the guidance of Prof. Silvio Danese. From January 1, 2021, to February 9, 2024, they worked as a Gastroenterologist at the IRCCS San Raffaele Hospital in Milan, Italy, in the Gastroenterology and Endoscopy Unit, also directed by Prof. Silvio Danese. 🏥📚🩺

Research focus

Based on the provided publications, the research focus appears to be on inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis. The studies address various aspects such as comparing treatments (e.g., tofacitinib vs. ustekinumab), assessing remission through non-invasive methods, and evaluating regulatory guidance for JAK inhibitors. The research also explores the use of biologics and other therapies in managing IBD, including switching between different treatment forms. This indicates a strong emphasis on optimizing treatment strategies and improving patient outcomes in IBD. 🌟📚💊

Publication top notes

Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study

Ultrasound remission after biologic induction and long-term endoscopic remission in Crohn’s disease: a prospective cohort study

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study

The role of filgotinib in ulcerative colitis and Crohn’s disease

A new national survey of centers for cognitive disorders and dementias in Italy

An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study

Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn’s disease

MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations

Advancing transmural remission as a treatment target in Crohn’s disease: The future of tight-control strategy?

Noninvasive Assessment of Postoperative Disease Recurrence in Crohn’s Disease: A Multicenter, Prospective Cohort Study on Behalf of the Italian Group for Inflammatory Bowel Disease

 

 

Bijo Mathew | Medicinal Chemistry | Best Researcher Award

Published on by Research Awards

Prof Dr. Bijo Mathew | Medicinal Chemistry | Best Researcher Award

Professor at Amrita School of Pharmacy India.

Prof. Dr. Bijo Mathew is a distinguished academic in pharmaceutical sciences, currently serving as a Professor at Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi. With a robust background in molecular docking and drug design using AutoDock 4.2, Biovia, and Glide, he contributes significantly as Section Editor for Coronaviruses (BenthamScience) and Editorial Member for several prestigious journals. Dr. Mathew’s teaching career spans from Assistant Professor to his current role, imparting knowledge across various institutions in India. He is a sought-after speaker, delivering talks internationally and nationally on drug design and medicinal chemistry. Recognized as one of the Top 2% Scientists by Stanford, he has received multiple awards including the Amrita Publication Research Award and Best International Collaborator Award. Dr. Mathew holds patents for compositions addressing neurological disorders, underscoring his commitment to advancing pharmaceutical research and education.

Professional Profiles:

🎓 Education

Prof. Dr. Bijo Mathew boasts a distinguished academic journey in pharmaceutical sciences, culminating in a Ph.D. from Jawaharlal Nehru Technological University, Hyderabad, India, specializing in Pharmaceutical Science. Prior to his doctoral studies, he completed his Master’s in Pharmaceutical Chemistry and Bachelor’s in Pharmacy at The Tamilnadu Dr. M.G.R. Medical University, Chennai, and his pre-degree at Mahatma Gandhi University, Kottayam, India. His doctoral research under the guidance of Dr. A. Jerad Suresh focused on the synthesis, characterization, and pharmacological evaluation of heterocyclic derivatives, contributing significantly to the field. Prof. Mathew’s academic journey is marked by a commitment to advancing pharmaceutical knowledge, evident in his extensive expertise across various domains of pharmaceutical research, including molecular docking, dynamics, and pharmacophore mapping. His educational foundation and research acumen continue to drive innovative contributions in drug discovery and development, positioning him as a prominent figure in academia and pharmaceutical research.

Area of Interest and Expertise

Prof. Dr. Bijo Mathew’s research interests encompass a diverse array of fields within pharmaceutical chemistry and drug discovery. His expertise spans the chemistry and biological exploration of various classes of compounds such as chalcones and isatins. He is involved in the synthesis and pharmacological evaluation of heterocyclic nuclei including benzimidazole, thiadiazole, pyrimidine, furan, pyrazoline, and thiazole derivatives, focusing on their potential as CNS depressants, anticonvulsants, anticancer agents, antioxidants, and neuroprotective compounds. Dr. Mathew specializes in designing inhibitors for key enzymes like MAO, AChE, BACE1, and Hsp90, utilizing techniques such as monowave-assisted synthesis and structural elucidation through IR, NMR, and MASS spectroscopy. His research also extends to molecular docking, dynamics, pharmacophore mapping, and 3D-QSAR studies, as well as the isolation and computational analysis of natural secondary metabolites from medicinal plants.

Expertise in Software:

  • AutoDock 4.2, Biovia, Glide

Editorial Contributions:

  • Section Editor for Coronaviruses (BenthamScience)
  • Editorial Member for Brain Sciences (MDPI), Combinatorial Chemistry & High Throughput Screening (Bentham Science), Molecules (MDPI), Current Topics in Medicinal Chemistry (Bentham Science), Current Drug Targets (Bentham Science)

Teaching Experience:

  • Professor at Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, India, since April 2022
  • Associate Professor and Assistant Professor at various institutions in India prior to current position

Invited Talks:

  • Presented internationally and nationally on topics related to drug design, molecular docking, and medicinal chemistry.

Awards and Recognition:

  • Recognized with multiple awards including Top 2% Scientists from Stanford, Amrita Publication Research Award, Best International Collaborator Award, Chancellor’s Publication Award, Publication Merit Award, and Best Resource Person Award at National College of Pharmacy.

Patents:

  • Granted patents on compositions for neurological disorders and therapeutic agents.

Publications

  1. Elucidating molecular mechanism and chemical space of chalcones through biological networks and machine learning approaches
    • Authors: Manaithiya, A., Bhowmik, R., Acharjee, S., Parkkila, S., Aspatwar, A., Mathew, B.
    • Year: 2024
    • Citations: 0
  2. Machine learning driven web-based app platform for the discovery of monoamine oxidase B inhibitors
    • Authors: Kumar, S., Bhowmik, R., Oh, J.M., Kim, H., Mathew, B.
    • Year: 2024
    • Citations: 3
  3. Development of morpholine ring-bearing halogenated α,β-unsaturated ketones as selective monoamine oxidase-B inhibitors
    • Authors: Lee, J., Parmbil, S.K., Pandit, N.K., Kim, H., Mathew, B.
    • Year: 2024
    • Citations: 0
  4. Isatin-tethered halogen-containing acylhydrazone derivatives as monoamine oxidase inhibitor with neuroprotective effect
    • Authors: Kumar, S., Oh, J.M., Prabhakaran, P., Kim, H., Mathew, B.
    • Year: 2024
    • Citations: 3
  5. MzDOCK: A free ready-to-use GUI-based pipeline for molecular docking simulations
    • Authors: Kabier, M., Gambacorta, N., Trisciuzzi, D., Nicolotti, O., Mathew, B.
    • Year: 2024
    • Citations: 0
  6. Design and Synthesis of the Linezolid Bioisosteres to Resolve the Serotonergic Toxicity Associated with Linezolid
    • Authors: Girase, R.T., Ahmad, I., Oh, J.M., Kim, H., Patel, H.M., Mathew, B.
    • Year: 2024
    • Citations: 0
  7. MAO-B Inhibitor (2E)-3-(4-Bromophenyl)-1-(1H-indol-3-yl) prop-2-en-1-one as a Neuroprotective Agent Against Alzheimer’s Disease
    • Authors: Sasidharan, R., Mohanan, R., Kukreti, N., Manju, S.L., Mathew, B.
    • Year: 2024
    • Citations: 0
  8. Correction to: Targeting cellular batteries for the therapy of neurological diseases (Environmental Science and Pollution Research)
    • Authors: Arora, A., Behl, T., Sehgal, A., Mathew, B., Bungau, S.
    • Year: 2024
    • Citations: 0
  9. Chalcones with N-Methylpiperazine Moiety: Synthesis, Monoamine Oxidase Inhibition, Neuroprotective Effect and Computer Simulation Study
    • Authors: Jayan, J., Trisciuzzi, D., Benny, F., Nicolotti, O., Mathew, B.
    • Year: 2024
    • Citations: 0
  10. A structure-based approach to explore novel COX-2 inhibitors using pharmacophore modelling, 3D-QSAR analysis, virtual screening and dynamics simulation study
    • Authors: Krishnendu, P.R., Benny, S., Kumar, S., Zachariah, S.M., Mathew, B.
    • Year: 2024
    • Citations: 3

 

 

Tugba Agbal | Medicine and Health Sciences | Best Researcher Award

Published on by Research Awards

Ms. Tugba Agbal | Medicine and Health Sciences | Best Researcher Award

Specialist Doctor at Ankara Etlik City Hospital, Turkey.

Dr. Tuğba Ağbal is a dedicated specialist in obstetrics and gynecology, currently serving at Etlik City Hospital. She completed her residency at The University of Health Sciences Etlik Zübeyde Hanım Gynecology Training and Research Hospital and earned her medical degree from Gazi University Faculty of Medicine. Dr. Ağbal’s professional experience includes significant roles at both Etlik City Hospital and Bulanık Public Hospital. Her research interests focus on reproductive health, prenatal and postnatal care, and innovative surgical techniques. She has received multiple awards and honors, including competency certificates in laparoscopic and hysteroscopic interventions, obstetric ultrasonography, neonatal resuscitation, and various therapeutic practices. Dr. Ağbal’s research skills are robust, encompassing clinical study design, statistical analysis, literature review, and collaboration. Her contributions to women’s health are marked by her compassionate approach to patient care and her commitment to advancing medical knowledge and improving clinical outcomes.

Professional Profiles:

Education 🎓

Tuğba Ağbal completed her Obstetrics and Gynecology Residency at The University of Health Sciences Etlik Zübeyde Hanım Gynecology Training and Research Hospital in Ankara, Turkey, from 2016 to 2021. Prior to her residency, she earned her medical degree from Gazi University Faculty of Medicine, also in Ankara, where she studied from 2009 to 2015. Her educational journey began at Hacı Ömer Tarman Science High School in Ankara, where she completed her high school education from 2005 to 2009.

Professional Experience

Since February 2023, Tuğba Ağbal has been working as a specialist in the Obstetrics and Gynecology Clinic at Etlik City Hospital. Prior to this, she served as a specialist in the Obstetrics and Gynecology Clinic at Bulanık Public Hospital from 2022 to 2023. Her professional journey has been marked by a dedication to women’s health, with a focus on providing comprehensive care in obstetrics and gynecology. During her tenure at these hospitals, she has gained extensive experience in managing a variety of cases, ranging from routine prenatal and postnatal care to complex gynecological surgeries. Dr. Ağbal’s commitment to her field is evident through her continuous pursuit of professional development and her active involvement in clinical practice, ensuring she stays at the forefront of medical advancements. Her work is characterized by a compassionate approach to patient care and a strong commitment to improving women’s health outcomes.

Research Interest

Tuğba Ağbal’s research interests are primarily focused on obstetrics and gynecology, with a particular emphasis on improving clinical outcomes and advancing medical knowledge in women’s health. She is deeply interested in the study of reproductive health, prenatal and postnatal care, and the management of gynecological disorders. Her work includes investigating innovative approaches to treat conditions such as pelvic floor organ prolapse and postpartum complications. Additionally, she is keen on exploring the impacts of various medical interventions on maternal and fetal health. Dr. Ağbal is also interested in the development and assessment of new methodologies for gynecological surgeries and minimally invasive techniques. Her research aims to enhance the understanding and treatment of female reproductive health issues, contributing to better patient care and outcomes.

Award and Honors

Tuğba Ağbal has received several awards and honors throughout her career. She was awarded the Laparoscopic Intervention Competency Achievement Certificate from The University of Health Sciences Etlik Zübeyde Hanım Gynecology Training and Research Hospital in Ankara, Turkey. She also earned the Hysteroscopic Intervention Competency Achievement Certificate from the same institution. Additionally, Dr. Ağbal completed training and received competency certification for basic obstetric ultrasonography in both the first and second trimesters. She has been recognized for her expertise in neonatal resuscitation by the Turkish Ministry of Health, General Directorate of Public Health, Department of Child and Adolescent Health. Furthermore, she holds certifications in colposcopy, divorce therapy, sexual therapy, and marriage and couple therapy from the Relationship Therapies Institute. These accolades highlight her dedication to professional development and excellence in her field.

Research Skills

Tuğba Ağbal possesses a comprehensive set of research skills that enhance her expertise in obstetrics and gynecology. She is proficient in designing and conducting clinical studies, particularly those related to women’s reproductive health. Her skills include statistical analysis and data interpretation, which are crucial for evaluating research outcomes and drawing meaningful conclusions. Dr. Ağbal is experienced in writing and reviewing scientific manuscripts, contributing to her ability to publish research findings in reputable journals. She is adept at using various research methodologies, including both qualitative and quantitative approaches, to explore complex medical issues. Additionally, her skills in literature review and meta-analysis enable her to synthesize existing research and identify gaps in knowledge. Dr. Ağbal’s ability to collaborate with multidisciplinary teams and her commitment to ethical research practices further underscore her capabilities as a researcher in the field of obstetrics and gynecology.